Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents

被引:67
作者
Zheng, QH
Fei, XS
Liu, X
Wang, JQ
Sun, HB
Mock, BH
Stone, KL
Martinez, TD
Miller, KD
Sledge, GW
Hutchins, GD
机构
[1] Indiana Univ, Sch Med, Dept Radiol, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Anat, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
关键词
matrix metalloproteinase inhibitor; breast cancer; radiotracer; C-11]methyl-halo-CGS 27023A analogs; positron emission tomography; carbon-11;
D O I
10.1016/S0969-8051(02)00338-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A series of [C-11]methyl-halo-CGS 27023A analogs (2-F, 1a; 4-F, 1b; 2-Cl, 1c; 3-Cl, 1d; 4-Cl, 1e; 2-Br, 1f; 3-Br, 1g; 4-Br, 1h; 4-I, 1i), novel radiolabeled matrix metalloproteinase (MMP) inhibitors, have been synthesized for evaluation as new potential positron emission tomography (PET) breast cancer imaging agents. The precursors halo-CGS 27023A analogs (2-F, 6a; 4-F, 6b; 2-Cl, 6c; 3-Cl, 6d; 4-Cl, 6e; 2-Br, 6f; 3-Br, 6g; 4-Br, 6h; 4-I, 6i) for radiolabeling were obtained in four steps from starting material amino acid D-valine with moderate to excellent chemical yields. Precursors were labeled by [C-11]methyl triflate through C-11-O-methylation method at the aminohydroxyl position under basic conditions and isolated by solid-phase extraction (SPE) purification to produce pure target compounds in 40-60% radiochemical yields (decay corrected to end of bombardment), in 20-25 min synthesis time. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:761 / 770
页数:10
相关论文
共 37 条
[1]  
Afzal S, 1996, LAB INVEST, V74, P406
[2]   Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors [J].
Almstead, NG ;
Bradley, RS ;
Pikul, S ;
De, B ;
Natchus, MG ;
Taiwo, YO ;
Gu, F ;
Williams, LE ;
Hynd, BA ;
Janusz, MJ ;
Dunaway, CM ;
Mieling, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (22) :4547-4562
[3]  
[Anonymous], ANN REP MED CHEM
[4]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[5]   Matrix metalloproteinase inhibitors [J].
Brown, PD .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :125-136
[6]   Potent and selective mechanism-based inhibition of gelatinases [J].
Brown, S ;
Bernardo, MM ;
Li, ZH ;
Kotra, LP ;
Tanaka, Y ;
Fridman, R ;
Mobashery, S .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (28) :6799-6800
[7]   Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold [J].
Cheng, MY ;
De, B ;
Almstead, NG ;
Pikul, S ;
Dowty, ME ;
Dietsch, CR ;
Dunaway, CM ;
Gu, F ;
Hsieh, LC ;
Janusz, MJ ;
Taiwo, YO ;
Natchus, MG ;
Hudlicky, T ;
Mandel, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (26) :5426-5436
[8]   Design and synthesis of piperazine-based matrix metalloproteinase inhibitors [J].
Cheng, MY ;
De, B ;
Pikul, S ;
Almstead, NG ;
Natchus, MG ;
Anastasio, MV ;
McPhail, SJ ;
Snider, CE ;
Taiwo, YO ;
Chen, LY ;
Dunaway, CM ;
Gu, F ;
Dowty, ME ;
Mieling, GE ;
Janusz, MJ ;
Wang-Weigand, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) :369-380
[9]   Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents [J].
Fei, XS ;
Zheng, QH ;
Hutchins, GD ;
Liu, X ;
Stone, KL ;
Carlson, KA ;
Mock, BH ;
Winkle, WL ;
Glick-Wilson, BE ;
Miller, KD ;
Fife, RS ;
Sledge, GW ;
Sun, HB ;
Carr, RE .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2002, 45 (06) :449-470
[10]  
GREENWALD RA, 1999, ANN NY ACAD SCI, V878, P1